Dyne Therapeutics is a clinical-stage biotechnology company developing oligonucleotide therapies for serious muscle diseases. Its FORCE platform aims to deliver genetic medicines more effectively into muscle tissue, with programs targeting conditions such as Duchenne muscular dystrophy, myotonic dystrophy type 1, and facioscapulohumeral muscular dystrophy. The company is pre-commercial and focused on advancing these candidates through clinical development.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -115.4 | — |
| Q2 2025 | 0 | — | -110.9 | — |
| Q3 2025 | 0 | — | -108 | — |
| Q4 2025 | 0 | — | -112 | — |
| Q1 2026 | 0 | — | -120.8 | — |
| Q2 2026 | 0 | — | -178.6 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: LifeStance Health Group, Inc. (LFST), Gentex Corporation (GNTX), UFP Industries, Inc. (UFPI), Insight Enterprises, Inc. (NSIT), The Chefs' Warehouse, Inc. (CHEF), Dave Inc. (DAVE)